Recombinant Human CD59 Protein (Leu26-Asn102), GST tagged

Cat.No. : CD59-0955H
Product Overview : Recombinant human CD59 (Leu26-Asn102) fused with GST tag was expressed in E. coli.
  • Specification
  • Gene Information
  • Related Products
  • Download
Description : Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.
Source : E. coli
Species : Human
Tag : GST
Form : Lyophilized powder/frozen liquid
Molecular Mass : 34.83 kDa
Protein Length : Leu26-Asn102
Purity : >90% as determined by SDS-PAGE.
Notes : For research use only.
Storage : Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 centigrade for one week.
Store at -20 to -80 centigrade for twelve months from the date of receipt.
Storage Buffer : Supplied as solution form in PBS pH 7.5 or lyophilized from PBS pH 7.5.
Reconstitution : Reconstitute in sterile water for a stock solution.
Shipping : They are shipped out with dry ice/blue ice unless customers require otherwise.
Gene Name : CD59 CD59 molecule, complement regulatory protein [ Homo sapiens (human) ]
Official Symbol : CD59
Synonyms : CD59; CD59 molecule, complement regulatory protein; CD59 antigen p18 20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344), CD59 antigen, complement regulatory protein, MIC11, MIN1, MIN2, MIN3, MSK21; CD59 glycoprotein; 16.3A5; EJ16; EJ30; EL32; G344; p18 20; protectin; 1F5 antigen; MEM43 antigen; Ly-6-like protein; T cell-activating protein; human leukocyte antigen MIC11; lymphocytic antigen CD59/MEM43; 20 kDa homologous restriction factor; membrane inhibitor of reactive lysis; membrane attack complex inhibition factor; membrane attack complex (MAC) inhibition factor; surface anitgen recognized by monoclonal 16.3A5; CD59 antigen p18-20 (antigen identified by monoclonal antibodies 16.3A5, EJ16, EJ30, EL32 and G344); 1F5; MIN1; MIN2; MIN3; MIRL; HRF20; MACIF; MEM43; MIC11; MSK21; HRF-20; MAC-IP; p18-20; MGC2354; FLJ38134; FLJ92039;
Gene ID : 966
mRNA Refseq : NM_000611
Protein Refseq : NP_000602
MIM : 107271
UniProt ID : P13987

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (6)

Ask a question
How to explain the role of CD59 in hemolytic disease? 11/30/2022

In hemolytic diseases, the deficiency or dysfunction of CD59 may lead to excessive lysis of red blood cells because the formation of the complement C5b-9 complex cannot be effectively prevented.

Are there differences in CD59 expression levels in different types of cells? 09/30/2022

Yes, the expression level of CD59 can vary in different cell types. In general, it is expressed higher in blood cells and some tumor cells.

What are some of the technical challenges that laboratories may encounter when researching CD59? 12/03/2021

When researching CD59, laboratories may encounter technical challenges such as selecting the appropriate assay, ensuring the quality and consistency of samples, and the complexity of interpreting results. In addition, CD59 expression variations in different cell types and experimental conditions need to be considered.

What diseases are associated with aberrant expression of CD59? 07/19/2020

Aberrant expression of CD59 has been associated with a variety of diseases, including but not limited to hemolytic diseases, certain types of cancer, and autoimmune diseases.

How can I measure CD59 expression in the laboratory? 06/17/2020

CD59 expression can be detected using flow cytometry, immunofluorescence staining, or western blotting.

Is there a current treatment for CD59? 01/01/1900

The current treatment for CD59 is still in the research stage, and there is no drug approved for clinical use. However, some studies are exploring the use of gene therapy or antibody therapy to modulate CD59 expression or function.

Customer Reviews (3)

Write a review
Reviews
05/09/2022

    The quality is very high and the reliability is very helpful for our research results.

    03/17/2021

      There are no doping impurities, the experimental effect is very good, and I will recommend it to other students.

      01/13/2021

        Easy to operate and cost-effective.

        Ask a Question for All CD59 Products

        Required fields are marked with *

        My Review for All CD59 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends